Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.96 USD | -0.86% |
|
-2.53% | -8.46% |
Jul. 04 | ANALYST RECOMMENDATIONS : Citigroup, Constellation Brands, Broadcom, JPMorgan, Bunzl... | ![]() |
Jul. 02 | Ipsen Expands Partnership with Exelixis for Cabometyx | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-8.46% | 6.4B | B | ||
+15.58% | 121B | B+ | ||
+16.60% | 110B | B+ | ||
+18.20% | 25.98B | B | ||
-24.33% | 19.27B | B+ | ||
-18.28% | 15.99B | A- | ||
-17.95% | 15.66B | B | ||
-48.32% | 14.5B | A- | ||
+58.78% | 14.47B | C+ | ||
+4.91% | 13.91B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- EXEL Stock
- Ratings Exelixis, Inc.